Patent ID: 7713954
Filing Date: 2010-05-11
Classification: A61K

Abstract:
1. A method of treating but not preventing cognitive dysfunction associated with a cognitive disorder comprising administering to a subject in need thereof a therapeutically effective amount of a compound which is a combined selective 5-HT6 receptor/5-HT2A receptor antagonist wherein said compound is selected formula V: wherein u is from 0 to 3; v is from 1 to 3; Ar is optionally substituted aryl or optionally substituted heteroaryl; each R 16 is independently halo, alkyl, haloalkyl, cyano, —SO 2 R f , —C(═O)—NR g R h , —SR g , —C(═O)—R g , where each R f , R g and R h is independently hydrogen or alkyl; R 17 and R 18 each independently is hydrogen or alkyl, or R 17 and R 18 together may form ═NR i wherein R i is hydrogen or alkyl; R 19 and R 20 each independently is hydrogen or alkyl, or one of R 19 and R 20 is hydrogen and the other is an optionally substituted heteroaryl, or R 19 and R 20 together with the nitrogen to which they are attached may form an amidinyl group, a urea group, a guanidinyl group, or a five- or six-membered ring that optionally includes an additional heteroatom selected from O, N and S, or one of R 19 and R 20 and one of R 17 and R 18 together with the atoms to which they are attached may form a five- or six-membered ring that optionally includes an additional heteroatom selected from O, N and S; and the pharmaceutically acceptable acid addition salts thereof.